{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:27:34Z","timestamp":1793672854021,"version":"4.5.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10072-026-09373-x","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:25:27Z","timestamp":1789097127000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of efgartigimod in the treatment of autoimmune encephalitis: a systematic review"],"prefix":"10.1007","volume":"47","author":[{"given":"Ping","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiqiang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0606-561X","authenticated-orcid":false,"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"9373_CR1","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/s1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus F, Titulaer MJ, Balu R et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15:391\u2013404. https:\/\/doi.org\/10.1016\/s1474-4422(15)00401-9","journal-title":"Lancet Neurol"},{"key":"9373_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/10408363.2023.2247482","volume":"61","author":"S Masciocchi","year":"2024","unstructured":"Masciocchi S, Businaro P, Scaranzin S, Morandi C, Franciotta D, Gastaldi M (2024) General features, pathogenesis, and laboratory diagnostics of autoimmune encephalitis. Crit Rev Clin Lab Sci 61:45\u201369. https:\/\/doi.org\/10.1080\/10408363.2023.2247482","journal-title":"Crit Rev Clin Lab Sci"},{"key":"9373_CR3","doi-asserted-by":"publisher","first-page":"577753","DOI":"10.1016\/j.jneuroim.2021.577753","volume":"361","author":"H Ren","year":"2021","unstructured":"Ren H, Fan S, Zhao Y, Guan H (2021) The changing spectrum of antibody-mediated encephalitis in China. J Neuroimmunol 361:577753. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577753","journal-title":"J Neuroimmunol"},{"key":"9373_CR4","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.4103\/0366-6999.180514","volume":"129","author":"HZ Guan","year":"2016","unstructured":"Guan HZ, Ren HT, Cui LY (2016) Autoimmune Encephalitis: An Expanding Frontier of Neuroimmunology. Chin Med J 129:1122\u20131127. https:\/\/doi.org\/10.4103\/0366-6999.180514","journal-title":"Chin Med J"},{"key":"9373_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00406-020-01113-2","volume":"270","author":"D Endres","year":"2020","unstructured":"Endres D, Leypoldt F, Bechter K et al (2020) Autoimmune encephalitis as a differential diagnosis of schizophreniform psychosis: clinical symptomatology, pathophysiology, diagnostic approach, and therapeutic considerations. Eur Arch Psychiatry Clin NeuroSci 270:803\u2013818. https:\/\/doi.org\/10.1007\/s00406-020-01113-2","journal-title":"Eur Arch Psychiatry Clin NeuroSci"},{"key":"9373_CR6","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1586\/14737175.2015.1115720","volume":"15","author":"M Nosadini","year":"2015","unstructured":"Nosadini M, Mohammad SS, Ramanathan S, Brilot F, Dale RC (2015) Immune therapy in autoimmune encephalitis: a systematic review. Expert Rev Neurother 15:1391\u20131419. https:\/\/doi.org\/10.1586\/14737175.2015.1115720","journal-title":"Expert Rev Neurother"},{"key":"9373_CR7","doi-asserted-by":"publisher","first-page":"790962","DOI":"10.3389\/fimmu.2021.790962","volume":"12","author":"J Yang","year":"2021","unstructured":"Yang J, Liu X (2021) Immunotherapy for Refractory Autoimmune Encephalitis. Front Immunol 12:790962. https:\/\/doi.org\/10.3389\/fimmu.2021.790962","journal-title":"Front Immunol"},{"key":"9373_CR8","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/s1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr., Bril V, Vu T et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20:526\u2013536. https:\/\/doi.org\/10.1016\/s1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"key":"9373_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40263-024-01090-3","volume":"38","author":"N Alfaidi","year":"2024","unstructured":"Alfaidi N, Karmastaji S, Matic A, Bril V (2024) FcRn Inhibitor Therapies in Neurologic Diseases. CNS Drugs 38:425\u2013441. https:\/\/doi.org\/10.1007\/s40263-024-01090-3","journal-title":"CNS Drugs"},{"key":"9373_CR10","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1007\/s10072-024-07678-3","volume":"45","author":"SQ Huang","year":"2024","unstructured":"Huang SQ, Yuan ZH, Hong Y, Jiang T, Zhao HD, Shi JQ (2024) Successful treatment with efgartigimod as an add-on therapy in acute attack of anti-AQP4 antibody-positive NMOSD: a case report. Neurol sciences: official J Italian Neurol Soc Italian Soc Clin Neurophysiol 45:5511\u20135515. https:\/\/doi.org\/10.1007\/s10072-024-07678-3","journal-title":"Neurol sciences: official J Italian Neurol Soc Italian Soc Clin Neurophysiol"},{"key":"9373_CR11","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1007\/s10072-024-07460-5","volume":"45","author":"Y Yang","year":"2024","unstructured":"Yang Y, Shen Z, Shi F, Wang F, Wen N (2024) Efgartigimod as a novel FcRn inhibitor for autoimmune disease. Neurol sciences: official J Italian Neurol Soc Italian Soc Clin Neurophysiol 45:4229\u20134241. https:\/\/doi.org\/10.1007\/s10072-024-07460-5","journal-title":"Neurol sciences: official J Italian Neurol Soc Italian Soc Clin Neurophysiol"},{"key":"9373_CR12","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1007\/s00415-024-12321-4","volume":"271","author":"H Zhang","year":"2024","unstructured":"Zhang H, Ma J, Feng Y et al (2024) Efgartigimod in the treatment of Guillain-Barr\u00e9 syndrome. J Neurol 271:3506\u20133511. https:\/\/doi.org\/10.1007\/s00415-024-12321-4","journal-title":"J Neurol"},{"key":"9373_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst reviews 10:89. https:\/\/doi.org\/10.1186\/s13643-021-01626-4","journal-title":"Syst reviews"},{"key":"9373_CR14","unstructured":"JBI\u2019s critical appraisal tools (Available from: https:\/\/jbi.global\/critical-appraisal-tools"},{"key":"9373_CR15","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.11124\/jbisrir-d-19-00099","volume":"18","author":"Z Munn","year":"2020","unstructured":"Munn Z, Barker TH, Moola S et al (2020) Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid synthesis 18:2127\u20132133. https:\/\/doi.org\/10.11124\/jbisrir-d-19-00099","journal-title":"JBI Evid synthesis"},{"key":"9373_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603\u2013605. https:\/\/doi.org\/10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"9373_CR17","doi-asserted-by":"publisher","unstructured":"Chen M, Bi Z, Kang W et al (2025) Resolution of anti-GAD-associated autoimmune encephalitis in patients treated with efgartigimod. Front Neurol 16. https:\/\/doi.org\/10.3389\/fneur.2025.1550023","DOI":"10.3389\/fneur.2025.1550023"},{"key":"9373_CR18","doi-asserted-by":"publisher","first-page":"106983","DOI":"10.1016\/j.imlet.2025.106983","volume":"273","author":"J Qin","year":"2025","unstructured":"Qin J, Li W, Yuan L, Liu H, Pang R, Zhang J (2025) Efficacy and safety of efgartigimod in patients with neurological autoimmune diseases. Immunol Lett 273:106983. https:\/\/doi.org\/10.1016\/j.imlet.2025.106983","journal-title":"Immunol Lett"},{"key":"9373_CR19","doi-asserted-by":"publisher","unstructured":"Chai S, Liu G, Zhang Y (2025) Anti-kelch-like protein 11 antibody-associated encephalitis: two case reports and literature review. BMC Neurol 25. https:\/\/doi.org\/10.1186\/s12883-025-04308-z","DOI":"10.1186\/s12883-025-04308-z"},{"key":"9373_CR20","doi-asserted-by":"publisher","unstructured":"Tu X, Liu X, Yang N, Sun D, Mei B, Yan N (2025) Successful sequential treatment with ofatumumab followed by efgartigimod for refractory autoimmune encephalitis with dual anti-NMDAR and anti-GFAP antibody positivity: first case report. Front Immunol 16. https:\/\/doi.org\/10.3389\/fimmu.2025.1640281","DOI":"10.3389\/fimmu.2025.1640281"},{"key":"9373_CR21","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s10072-024-07843-8","volume":"46","author":"J Xu","year":"2025","unstructured":"Xu J, Guo Z, Zhao J, Chen Y, Liu Z, Wu Y (2025) Efgartigimod treatment for therapy-refractory autoimmune encephalitis with coexistent NMDAR and LGI1 antibodies: a case report and literature review. Neurol Sci 46:1995\u20132005. https:\/\/doi.org\/10.1007\/s10072-024-07843-8","journal-title":"Neurol Sci"},{"key":"9373_CR22","doi-asserted-by":"publisher","unstructured":"Bi Z, Kang W, Liu R, Jiang Y, Chen M (2025) Efgartigimod as a fast-acting add\u2010on therapy in antibody\u2013mediated autoimmune encephalitis. Eur J Neurol 32. https:\/\/doi.org\/10.1111\/ene.70280","DOI":"10.1111\/ene.70280"},{"key":"9373_CR23","doi-asserted-by":"publisher","unstructured":"Bian Z, Cai H, Wu H et al (2025) Safety and efficacy of a neonatal Fc receptor antagonist in patients with anti-NMDAR encephalitis. CNS Neurosci Ther 31. https:\/\/doi.org\/10.1111\/cns.70534","DOI":"10.1111\/cns.70534"},{"key":"9373_CR24","doi-asserted-by":"publisher","unstructured":"Huang H, Wei Y, Qin H, Han G, Li J (2025) Successful treatment with efgartigimod as an add-on therapy for acute attack of anti-NMDA receptor encephalitis: a case report. BMC Neurol 25. https:\/\/doi.org\/10.1186\/s12883-025-04034-6","DOI":"10.1186\/s12883-025-04034-6"},{"key":"9373_CR25","doi-asserted-by":"publisher","unstructured":"Liu J, Li M, Liu J et al (2025) Multicenter experience with Efgartigimod in the treatment of anti-NMDAR encephalitis compared with IVIG and SPA-IA during acute attacks. Life Sci 371. https:\/\/doi.org\/10.1016\/j.lfs.2025.123597","DOI":"10.1016\/j.lfs.2025.123597"},{"key":"9373_CR26","doi-asserted-by":"publisher","unstructured":"Zhang Q, Yang W, Qian Y et al (2024) Case report: Rapid symptom relief in autoimmune encephalitis with efgartigimod: a three-patient case series. Front Immunol 15. https:\/\/doi.org\/10.3389\/fimmu.2024.1444288","DOI":"10.3389\/fimmu.2024.1444288"},{"key":"9373_CR27","doi-asserted-by":"publisher","first-page":"e42436","DOI":"10.1097\/md.0000000000042436","volume":"104","author":"L Shen","year":"2025","unstructured":"Shen L, Liu H, Liu X et al (2025) An adolescent patient with anti-N-methyl-D-aspartate receptor encephalitis with motor aphasia as the first symptom and complicated by peripheral nerve damage: A case report and literature review. Medicine 104:e42436. https:\/\/doi.org\/10.1097\/md.0000000000042436","journal-title":"Medicine"},{"key":"9373_CR28","doi-asserted-by":"publisher","first-page":"5911","DOI":"10.1007\/s00415-024-12556-1","volume":"271","author":"F Zhu","year":"2024","unstructured":"Zhu F, Wang W-F, Ma C-H, Liang H, Jiang Y-Q (2024) Resolution of anti-LGI1-associated autoimmune encephalitis in a patient after treatment with efgartigimod. J Neurol 271:5911\u20135915. https:\/\/doi.org\/10.1007\/s00415-024-12556-1","journal-title":"J Neurol"},{"key":"9373_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11940-020-0616-8","volume":"22","author":"A Patel","year":"2020","unstructured":"Patel A, Lynch F, Shepherd SA (2020) Newer Immunotherapies for the Treatment of Acute Neuromuscular Disease in the Critical Care Unit. Curr Treat options Neurol 22:7. https:\/\/doi.org\/10.1007\/s11940-020-0616-8","journal-title":"Curr Treat options Neurol"},{"key":"9373_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/ana.25002","volume":"82","author":"MC Dalakas","year":"2017","unstructured":"Dalakas MC, Rakocevic G, Dambrosia JM, Alexopoulos H, McElroy B (2017) A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome. Ann Neurol 82:271\u2013277. https:\/\/doi.org\/10.1002\/ana.25002","journal-title":"Ann Neurol"},{"key":"9373_CR31","doi-asserted-by":"publisher","first-page":"578431","DOI":"10.1016\/j.jneuroim.2024.578431","volume":"395","author":"Y Hong","year":"2024","unstructured":"Hong Y, Gao L, Huang SQ et al (2024) Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: A single-center case series. J Neuroimmunol 395:578431. https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578431","journal-title":"J Neuroimmunol"},{"key":"9373_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/practneurol-2021-003073","volume":"22","author":"S Binks","year":"2022","unstructured":"Binks S, Uy C, Honnorat J, Irani SR (2022) Paraneoplastic neurological syndromes: a practical approach to diagnosis and management. Pract Neurol 22:19\u201331. https:\/\/doi.org\/10.1136\/practneurol-2021-003073","journal-title":"Pract Neurol"},{"key":"9373_CR33","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1001\/jamaneurol.2020.2231","volume":"77","author":"D Dubey","year":"2020","unstructured":"Dubey D, Wilson MR, Clarkson B et al (2020) Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis. JAMA Neurol 77:1420\u20131429. https:\/\/doi.org\/10.1001\/jamaneurol.2020.2231","journal-title":"JAMA Neurol"},{"key":"9373_CR34","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/cco.0000000000000222","volume":"27","author":"R H\u00f6ftberger","year":"2015","unstructured":"H\u00f6ftberger R, Rosenfeld MR, Dalmau J (2015) Update on neurological paraneoplastic syndromes. Curr Opin Oncol 27:489\u2013495. https:\/\/doi.org\/10.1097\/cco.0000000000000222","journal-title":"Curr Opin Oncol"},{"key":"9373_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11864-023-01157-1","volume":"25","author":"MJ Jean","year":"2024","unstructured":"Jean MJ, Samkoff L, Mohile N (2024) Management of Paraneoplastic Syndromes in the Era of Immune Checkpoint Inhibitors. Curr Treat Options Oncol 25:42\u201365. https:\/\/doi.org\/10.1007\/s11864-023-01157-1","journal-title":"Curr Treat Options Oncol"},{"key":"9373_CR36","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1002\/acn3.51486","volume":"8","author":"A Dik","year":"2021","unstructured":"Dik A, Widman G, Schulte-Mecklenbeck A et al (2021) Impact of T cells on neurodegeneration in anti-GAD65 limbic encephalitis. Ann Clin Transl Neurol 8:2289\u20132301. https:\/\/doi.org\/10.1002\/acn3.51486","journal-title":"Ann Clin Transl Neurol"},{"key":"9373_CR37","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/brain\/awac404","volume":"146","author":"AR Tr\u00f6scher","year":"2023","unstructured":"Tr\u00f6scher AR, Mair KM, Verd\u00fa de Juan L et al (2023) Temporal lobe epilepsy with GAD antibodies: neurons killed by T cells not by complement membrane attack complex. Brain 146:1436\u20131452. https:\/\/doi.org\/10.1093\/brain\/awac404","journal-title":"Brain"},{"key":"9373_CR38","doi-asserted-by":"publisher","first-page":"990553","DOI":"10.3389\/fneur.2022.990553","volume":"13","author":"L Bai","year":"2022","unstructured":"Bai L, Ren H, Liang M et al (2022) Neurological disorders associated with glutamic acid decarboxylase 65 antibodies: Clinical spectrum and prognosis of a cohort from China. Front Neurol 13:990553. https:\/\/doi.org\/10.3389\/fneur.2022.990553","journal-title":"Front Neurol"},{"key":"9373_CR39","doi-asserted-by":"publisher","first-page":"e954","DOI":"10.1097\/md.0000000000000954","volume":"94","author":"P Zdziarski","year":"2015","unstructured":"Zdziarski P (2015) A Case of Stiff Person Syndrome: Immunomodulatory Effect of Benzodiazepines: Successful Rituximab and Tizanidine Therapy. Medicine 94:e954. https:\/\/doi.org\/10.1097\/md.0000000000000954","journal-title":"Medicine"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09373-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09373-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09373-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:02:07Z","timestamp":1793671327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09373-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["9373"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09373-x","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"3 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The review does not contain clinical studies or patient data.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors confirm that there are no conflicts of interest.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CRD420251232760.","order":3,"name":"Ethics","label":"PROSPERO registration number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"770"}}